Does Discontinuing Teriparatide Treatment and Replacing It with Bisphosphonate Maintain the Volume of the Bone Fusion Mass after Lumbar Posterolateral Fusion in Women with Postmenopausal Osteoporosis?
- PMID: 28443172
- PMCID: PMC5401842
- DOI: 10.4184/asj.2017.11.2.272
Does Discontinuing Teriparatide Treatment and Replacing It with Bisphosphonate Maintain the Volume of the Bone Fusion Mass after Lumbar Posterolateral Fusion in Women with Postmenopausal Osteoporosis?
Abstract
Study design: Retrospective case series.
Purpose: The purpose of this study was to determine whether discontinuing teriparatide treatment and replacing it with bisphosphonate treatment maintains the volume of the fusion mass after posterolateral fusion (PLF) in women with postmenopausal osteoporosis.
Overview of literature: Clinical data support the efficacy of parathyroid hormone (PTH) for lumbar PLF. However, the use of PTH is limited to 2 years.
Methods: We treated 19 women diagnosed with osteoporosis and degenerative spondylolisthesis with teriparatide (20 µg daily subcutaneously). All patients underwent one-level instrumented PLF. Teriparatide was used during 2 months prior to surgery and more than 8 months after surgery. After discontinuing teriparatide treatment, all patients used bisphosphonate (17.5 mg risedronate weekly, oral administration). Area of the fusion mass across the transverse processes at one segment was determined on an anteroposterior radiograph at 1, 2, and 3 years after surgery.
Results: We followed 19 patients for 3 years. The average duration of teriparatide treatment was 11.5 months. The bone union rate was 95%. The average area of the bone fusion mass was not significantly different between the right and left sides at 1, 2, or 3 years after surgery (p>0.05).
Conclusions: This study showed that replacing teriparatide treatment with bisphosphonate maintained the bone fusion mass volume after PLF in women with postmenopausal osteoporosis.
Keywords: Fusion; Lumbar; Osteoporosis; Spine; Surgery; Teriparatide.
Conflict of interest statement
Conflict of Interest: No potential conflict of interest relevant to this article was reported.
Figures


Similar articles
-
Teriparatide accelerates lumbar posterolateral fusion in women with postmenopausal osteoporosis: prospective study.Spine (Phila Pa 1976). 2012 Nov 1;37(23):E1464-8. doi: 10.1097/BRS.0b013e31826ca2a8. Spine (Phila Pa 1976). 2012. PMID: 22872218 Clinical Trial.
-
More than 6 Months of Teriparatide Treatment Was More Effective for Bone Union than Shorter Treatment Following Lumbar Posterolateral Fusion Surgery.Asian Spine J. 2015 Aug;9(4):573-80. doi: 10.4184/asj.2015.9.4.573. Epub 2015 Jul 28. Asian Spine J. 2015. PMID: 26240717 Free PMC article.
-
Comparison of teriparatide and bisphosphonate treatment to reduce pedicle screw loosening after lumbar spinal fusion surgery in postmenopausal women with osteoporosis from a bone quality perspective.Spine (Phila Pa 1976). 2013 Apr 15;38(8):E487-92. doi: 10.1097/BRS.0b013e31828826dd. Spine (Phila Pa 1976). 2013. PMID: 23354115 Clinical Trial.
-
A review of teriparatide and its clinical efficacy in the treatment of osteoporosis.Expert Opin Pharmacother. 2004 May;5(5):1153-62. doi: 10.1517/14656566.5.5.1153. Expert Opin Pharmacother. 2004. PMID: 15155114 Review.
-
Teriparatide: a review.Clin Ther. 2004 Jun;26(6):841-54. doi: 10.1016/s0149-2918(04)90128-2. Clin Ther. 2004. PMID: 15262455 Review.
Cited by
-
Therapeutic Effect of Teriparatide for Osteoporotic Thoracolumbar Burst Fracture in Elderly Female Patients.J Korean Neurosurg Soc. 2020 Nov;63(6):794-805. doi: 10.3340/jkns.2020.0110. Epub 2020 Oct 27. J Korean Neurosurg Soc. 2020. PMID: 33105532 Free PMC article.
-
Anabolic agents: what is beyond osteoporosis?Osteoporos Int. 2018 May;29(5):1009-1022. doi: 10.1007/s00198-018-4507-8. Epub 2018 Apr 7. Osteoporos Int. 2018. PMID: 29627891 Free PMC article. Review.
-
Positive Effects of Bisphosphonates on Osteogenic Differentiation in Patient-Derived Mesenchymal Stem Cells for the Treatment of Osteoporosis.Tissue Eng Regen Med. 2018 Jun 8;15(4):467-475. doi: 10.1007/s13770-018-0127-9. eCollection 2018 Aug. Tissue Eng Regen Med. 2018. PMID: 30603570 Free PMC article.
-
Abaloparatide and the Spine: A Narrative Review.Clin Interv Aging. 2020 Jun 29;15:1023-1033. doi: 10.2147/CIA.S227611. eCollection 2020. Clin Interv Aging. 2020. PMID: 32636617 Free PMC article. Review.
References
-
- Bae HW, Rajaee SS, Kanim LE. Nationwide trends in the surgical management of lumbar spinal stenosis. Spine (Phila Pa 1976) 2013;38:916–926. - PubMed
-
- McGovern SC, Fong W, Wang JC. Can bone morphogenetic protein binding peptide increase efficiency of bone formation? Spine (Phila Pa 1976) 2010;35:1655–1659. - PubMed
-
- Dempster DW, Cosman F, Kurland ES, et al. Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res. 2001;16:1846–1853. - PubMed
-
- Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344:1434–1441. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials